The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder.本發明的醫藥組成物包含在醫藥學上可接受的載體中的(1)2-羥喹啉衍生物和(2)血清素再吸收抑制劑。2-羥喹啉衍生物可為阿立派唑(aripiprazole)或其代謝物，其為多巴胺-血清素系統安定劑。血清素再吸收抑制劑可為氟西汀(fluoxetine)、杜羅西汀(duloxetine)、文拉法辛(venlafaxine)、米那西藍(milnacipran)、西泰普蘭(citalopram)、氟伏沙明(fluvoxamine)、帕羅西汀(paroxetine)或舍曲林(sertraline)。本發明的醫藥組成物可用於治療患有心境障礙，特別是抑鬱或重大抑鬱障礙之病人。
